Ring In A Substituent E Patents (Class 564/217)
  • Publication number: 20150105587
    Abstract: An amorphous amide compound of the formula wherein R is selected from the group consisting of an alkyl group, an aryl group, an alkylaryl group, an arylalkyl group, and combinations thereof. An amorphous diamide compound of the formula wherein R1 is selected from the group consisting of an alkylene group, an arylene group, an alkylarylene group, an arylalkylene group, and combinations thereof.
    Type: Application
    Filed: October 14, 2013
    Publication date: April 16, 2015
    Applicant: Xerox Corporation
    Inventors: Naveen Chopra, Adela Goredema, Kentaro Morimitsu, Barkev Keoshkerian, Jennifer L. Belelie
  • Publication number: 20140275245
    Abstract: Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 18, 2014
    Applicant: KALYRA PHARMACEUTICALS, INC.
    Inventor: Kevin Duane Bunker
  • Patent number: 8796468
    Abstract: Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein R10 is a group represented by the formula: —(CR13R14)m-NR12—R11 or the like.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: August 5, 2014
    Assignee: Shionogi & Co., Ltd.
    Inventors: Tomoyuki Ogawa, Koji Masuda
  • Patent number: 8796491
    Abstract: The present invention pertains to process for the amidation of a substituted 1-bromo-adamantane comprising a step (0) of reacting a substituted adamantane with an excess of bromine to obtain a 1-bromo-adamantane and a step (i) of reacting said substituted 1-bromo-adamantane with an amide, wherein the substituted 1-bromo-adamantane is used in the form of a mixture comprising bromine as obtained in step (0), wherein in step (0) a bromine: substituted adamantane molar ratio of from [2.5:1] to less than [5:1] is employed.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: August 5, 2014
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Markus-Rene Gold, Herbert Koller, Michael Pyerin
  • Patent number: 8664441
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 4, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Patent number: 8501994
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 6, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Patent number: 8436209
    Abstract: The present invention relates to a process for manufacturing N-Formyl-1-amino-3,5-dimethyladamantane, an intermediate product in the overall process of producing 1-Amino-3,5-dimethyladamantane hydrochloride (Memantine). Therein, the process comprises the following steps: (a) reacting 1,3-dimethyladamantane with an acid mixture comprising concentrated sulfuric acid and concentrated nitric acid, wherein 1 to 6 volume parts of sulfuric acid (measured in ml) are used per weight part of 1,3-dimethyladamantane (measured in g); (b) reacting the solution from step (a) with an amount of formamide varying from 1 to 5 molar equivalents per mole of deprotonated 1,3-dimethyladamantane from step (a) to obtain N-Formyl-1-amino-3,5-dimethyladamantane. In step (b), the molar ratio of total acid, i.e. the molar amount of sulfuric acid and the molar amount of nitric acid taken together versus the molar amount of formamide is at least 1.5 and that the temperature is at least 50° C.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 7, 2013
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Florian Anton Martin Huber, Giorgio Gallo, Carla De Faveri
  • Patent number: 8436210
    Abstract: The present invention provides an amide compound having antibacterial activity, and a bacterial infection control agent for agricultural and horticultural use that contains the amide compound. The novel amide compound of the present invention is represented by General Formula (1): wherein R is a —CH(R1)(R2) or a —CO(R2) group, R1 is a hydrogen atom or a hydroxyl group, and R2 is a C1-12 alkyl group.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 7, 2013
    Assignees: The University of Tokyo, Otsuka Chemical Co., Ltd.
    Inventors: Hiroaki Suga, Jun Igarashi
  • Patent number: 8314270
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: November 20, 2012
    Assignee: Abbott Laboratories
    Inventors: James T. Link, Qi Shuai, Martin Winn, Hong Yong
  • Publication number: 20120270901
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 25, 2012
    Applicant: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Publication number: 20120259128
    Abstract: Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein R10 is a group represented by the formula: —(CR13R14)m-NR12—R11 or the like.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 11, 2012
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Tomoyuki Ogawa, Koji Masuda
  • Patent number: 8138375
    Abstract: The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: March 20, 2012
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20120040930
    Abstract: The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.
    Type: Application
    Filed: January 13, 2006
    Publication date: February 16, 2012
    Inventors: Catherine Guillou, Jean-Yves Lallemand, Thibault Sauvaítre, Jordi Molgo, Denyse Herlem, Daniel Guenard, Françoise Khuong-Huu
  • Publication number: 20110263900
    Abstract: The present invention pertains to process for the amidation of a substituted 1-bromo-adamantane comprising a step (0) of reacting a substituted adamantane with an excess of bromine to obtain a 1-bromo-adamantane and a step (i) of reacting said substituted 1-bromo-adamantane with an amide, wherein the substituted 1-bromo-adamantane is used in the form of a mixture comprising bromine as obtained in step (0), wherein in step (0) a bromine:substituted adamantane molar ratio of from [2.5:1] to less than [5:1] is employed.
    Type: Application
    Filed: August 7, 2009
    Publication date: October 27, 2011
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Markus-Rene Gold, Herbert Koller, Michael Pyerin
  • Publication number: 20110218214
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: September 9, 2010
    Publication date: September 8, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: James T. Link, Qi Shuai, Martin Winn, Hong Yong
  • Publication number: 20110200549
    Abstract: Disclosed are compounds having the ability to modulate, namely to improve, enhance and/or modify fragrance compositions due to their ability to inhibit cytochrome P450 enzymes, e.g. CYP2A, e.g. 2A13 and 2A6, and CYP2B6.
    Type: Application
    Filed: September 29, 2009
    Publication date: August 18, 2011
    Inventors: Thierry Granier, Boris Schilling
  • Publication number: 20110082317
    Abstract: The present invention relates to a process for manufacturing N-Formyl-1-amino-3,5-dimethyladamantane, an intermediate product in the overall process of producing 1-Amino-3,5-dimethyladamantane hydrochloride (Memantine). Therein, the process comprises the following steps: (a) reacting 1,3-dimethyladamantane with an acid mixture comprising concentrated sulfuric acid and concentrated nitric acid, wherein 1 to 6 volume parts of sulfuric acid (measured in ml) are used per weight part of 1,3-dimethyladamantane (measured in g); (b) reacting the solution from step (a) with an amount of formamide varying from 1 to 5 molar equivalents per mole of deprotonated 1,3-dimethyladamantane from step (a) to obtain N-Formyl-1-amino-3,5-dimethyladamantane. In step (b), the molar ratio of total acid, i.e. the molar amount of sulfuric acid and the molar amount of nitric acid taken together versus the molar amount of formamide is at least 1.5 and that the temperature is at least 50° C.
    Type: Application
    Filed: March 19, 2009
    Publication date: April 7, 2011
    Inventors: Florian Anton Martin Huber, Giorgio Gallo, Carla De Faveri
  • Publication number: 20100261920
    Abstract: The present invention provides an amide compound having antibacterial activity, and a bacterial infection control agent for agricultural and horticultural use that contains the amide compound. The novel amide compound of the present invention is represented by General Formula (1): wherein R is a —CH(R1)(R2) or a —CO(R2) group, R1 is a hydrogen atom or a hydroxyl group, and R2 is a C1-12 alkyl group.
    Type: Application
    Filed: November 6, 2008
    Publication date: October 14, 2010
    Applicants: THE UNIVERSITY OF TOKYO, OTSUKA CHEMICAL CO., LTD.
    Inventors: Hiroaki Suga, Jun Igarashi
  • Publication number: 20100120031
    Abstract: The present invention concerns methods of synthesis of trans-tert-butyl-2-aminocylcopentylcarbamate comprising contacting 6-tosyl-6-azabicyclo[3.1.0]hexane with TMSN3 and TBAF to produce 2-azido-N-tosylcyclopentananiine; reducing the 2-azido-N-tosylcyclopentanamine to produce 2-amino-N-tosylcyclopentanamine; contacting the 2-amino-N-tosylcyclopentanamine with di-tert/-butyl dicarbonate to produce tert-butyl-2-(tosylamino)cyclopentylcarbamate; and detosylation of tert-butyl O(tosylamino) cyclopentylcarbamate to produce trans-tert-butyl-2-aminocyclopentylcarbamate. The invention also concerns PNAs comprising residues of the monomers of the invention in the backbone and uses of such PNAs. The PNAs of the invention can be used to detect DNAs of infectious agents or to suppress expression of protein associated with cancer.
    Type: Application
    Filed: September 21, 2007
    Publication date: May 13, 2010
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF
    Inventors: Daniel H. Appella, Qun Xu, Ning Zhang
  • Publication number: 20100036153
    Abstract: The invention at hand provides at least dinitroxylated diamantanes. In addition, it provides methods for producing substituted diamantanes with high yields and selectivity. According to the invention, dinitroxylated diamantanes are suitable for being reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, it was discovered that at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid, creating at least 4,9-nitroxylated or hydroxylated diamantanes. On the basis of this, 4,9-substituted diamantanes are able to be produced in a targeted manner by reaction with further nucleophiles.
    Type: Application
    Filed: December 4, 2006
    Publication date: February 11, 2010
    Inventors: Peter R. Schreiner, Andrey A. Fokin
  • Publication number: 20090299097
    Abstract: The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids.
    Type: Application
    Filed: February 20, 2007
    Publication date: December 3, 2009
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20090299096
    Abstract: The invention relates to 1-formamido-adamantane derivatives of formula (I), which carry the substituents R1, R2 or R3 in 3, 5 and/or 7 position, the substituents being defined as follows: hydrogen, a linear or branched alkyl, alkenyl or alkinyl group with up to 6 C atoms, an aliphatic or aromatic, cyclic or heterocyclic hydrocarbon group with up to 10 carbon atoms, and formamides of hydrocarbons from the group of diamondoids, for example diamantane, triamantane, tetramantane and pentamantane, however, with the exception of 1-formamido-3,5-dimethyladamantane. The invention also relates to a method for the direct formation of formamide or acetamide of adamantane, adamantane derivatives with the aforementioned definition of substituents or of a hydrocarbon from the group of diamondoids, characterized by reacting the adamantane, the adamantane derivative or the diamondoid with formamide, acetamide or acetonitrile in concentrated acids, while avoiding SO3 containing sulfuric acid or 100% azotic acid.
    Type: Application
    Filed: February 20, 2007
    Publication date: December 3, 2009
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20090176886
    Abstract: The present invention relates to polymorphic forms of (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester phosphate, which is a potent inhibitor of viral neuraminidase.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 9, 2009
    Inventors: Andre Bubendorf, Pierre Goldbach, Olaf Grassmann, Michael Henning, Ines Sauer, Rene Trussardi
  • Patent number: 7511175
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: March 31, 2009
    Assignee: Abbott Laboratories
    Inventors: Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Peer B. Jacobson, Michael E. Brune
  • Publication number: 20080275112
    Abstract: The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs.
    Type: Application
    Filed: July 22, 2005
    Publication date: November 6, 2008
    Inventors: Peter R. Schreiner, Lukas Wanka
  • Patent number: 7405324
    Abstract: The present invention concerns a new process for synthesising aminoadamantanes of formula I in which R1 and R2 are identical or different and are H or a straight or branched alkyl group comprising from 1 to 6 carbon atoms, and addition salts thereof with inorganic or organic acids, in particular memantine hydrochloride (1-amino-3,5-dimethyladamantane hydrochloride).
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: July 29, 2008
    Assignee: A.M.S.A. Anonima Materie Sintetiche E. Afini S.p.A.
    Inventors: Enrico Vigano′, Ernesto Landonio, Simona Lanfranconi, Renato Molteni
  • Patent number: 7166744
    Abstract: The present invention relates to a novel retinoid derivative compound represented by the formula I: wherein X, R1, R2 and R3 are as defined herein or pharmaceutically acceptalbe salts thereof. Also, the present invention relates to processes for producing the compound of the formula I and to an anti-cancer composition comprising the compound of the formula I. The compound of the formula I according to the present invention exerts high anti-cancer effects while not causing undesirable side effects.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: January 23, 2007
    Assignee: Chebigen Co., Ltd.
    Inventors: Hong-Sig Sin, Soo-Jong Um, Young-Soy Rho, Si-Ho Park, Youn-Ja Kwon, Myoung-Soon Park, Hye-Sook Han, So-Mi Kim, Dong-Myoung Kim, Deok-Kun Oh, Jong-Sup Park, Tae-Sung Bae
  • Publication number: 20040235836
    Abstract: The present application describes modulators of MCP-1 of formula (I): 1
    Type: Application
    Filed: April 29, 2004
    Publication date: November 25, 2004
    Inventor: Robert J. Cherney
  • Patent number: 6790992
    Abstract: The present invention relates to novel scyphostatin analogues, which distinguish themselves by acting as SMase inhibitors so that they are of therapeutic use for a number of diseases such as a HIV infection, neurodegenerative diseases, inflammatory diseases, apoplexy, ischemia, myocardial infarction or in the case of atherosclerosis.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: September 14, 2004
    Assignee: Biofrontera Pharmaceuticals GmbH
    Inventor: Hans-Peter Deigner
  • Patent number: 6770784
    Abstract: Gamma-hydroxybutryic acid amides are used in the treatment of drug addiction and especially in the treatment of alcoholism.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: August 3, 2004
    Assignee: Laboratorio Farmaceutico C.T. S.r.l.
    Inventors: Roberto Cacciaglia, Antonella Loche, Vincenzo Perlini, Lorenza Guano
  • Patent number: 6767925
    Abstract: A sprayable analgesic composition containing an analgesic which is absorbed into the bloodstream through the buccal mucosa and a pharmacologically acceptable liquid carrier.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: July 27, 2004
    Inventor: Joseph A. Deihl
  • Patent number: 6756500
    Abstract: A process for preparing a cyclic compound comprising subjecting a starting material in the presence of a catalyst component to metathesis reaction in the presence of an ionic liquid, wherein the starting material is a &agr;,&ohgr;-diene bearing a &agr; substituent NRR1 in the &agr; position to a double bond, wherein R is hydrogen or an organic substituent, R1 is tert-butyl, P(R)2, P(R2)2, COR, SO2PhR, COOR or CONRR2, R2is alkyl or phenyl, or R and R1 together form and in which &agr;,&ohgr;-dienes optionally bear at least one further substituent R in any other position with the exception of the &agr; position, wherein R is selected from the group consisting of hydrogen, fused or unfused aryl, alkyl, CN, COOR2 or halogen, and wherein the starting material optionally contains a member selected from the group containing at least one further substituent that is inert in the metathesis reaction and a heteroatom selected from the group consisting of branched alkyl radicals, unbranched alkyl radical
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: June 29, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Christoph Gürtler, Manfred Jautelat
  • Patent number: 6706765
    Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: March 16, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L. Fedde, Carl R. Illig, Thomas P. Markotan, Thomas P. Stagnaro
  • Patent number: 6518310
    Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: February 11, 2003
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L Fedde, Carl R Illig, Thomas P. Markotan, Thomas P Stagnaro
  • Publication number: 20020165264
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: January 14, 2002
    Publication date: November 7, 2002
    Inventors: Michael E. Kort, Robert J. Gregg, William A. Carroll, Arturo Perez Medrano, Jurgen Dinges, Fatima Z. Basha
  • Publication number: 20020147230
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: February 7, 2001
    Publication date: October 10, 2002
    Inventors: Michael E. Kort, Robert J. Gregg, William A. Carroll, Arturo Perez Medrano, Jurgen Dinges
  • Patent number: 6441232
    Abstract: There is provided a method of selectively replacing a carbon-hydrogen bond at an unactivated saturated sp3 hybridised carbon atom in an organic compound by a carbon-nitrogen bond, the method comprising reacting the compound with a fluorinating agent in a solvent reaction medium comprising a nitrile compound and providing a Lewis acid whereby the carbon-hydrogen bond is replaced by a carbon-nitrogen bond. Advantageously, the reaction may be performed in one stage and/or in one vessel. Advantageously, the method may be carried out at or just below ambient or room temperature.
    Type: Grant
    Filed: January 1, 2002
    Date of Patent: August 27, 2002
    Assignee: F2 Chemicals Ltd.
    Inventors: Richard Dickinson Chambers, Mandy Parsons, Graham Sandford
  • Patent number: 6326369
    Abstract: A compound of the formula: wherein R1 and R2 each represents a lower alkyl, or R1 and R2 may be bonded together to form a ring; X represents a spacer of which the number of atoms constituting the principal chain is 1 to 15; Y represents an acyl, or a hydroxy, an amino or an aromatic group, each of which may be substituted; and ring A represents a 5- to 8-membered ring which may be further substituted apart from —X—Y, or a salt thereof is useful as a pharmaceutical composition for preventing or treating disease related to mitochondrial dysfunction.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: December 4, 2001
    Assignee: Takeda Chemicals Industries, Ltd.
    Inventors: Kaneyoshi Kato, Taiichi Ohra, Masaomi Miyamoto
  • Patent number: 6262308
    Abstract: The invention relates to a process for preparing cis-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, or racemic sertraline, corresponding to formula (I) in salt form, starting with 4-(3,4-dichlorophenyl)tetralone of formula (II) according to which (a) the 4-(3,4-dichlorophenyl)tetralone of formula (II) is reacted with N-methylformamide in the presence of formic acid, (b) the reaction medium obtained according to (a) is treated with a base, and (c) the racemic sertraline salt is separated out by selective crystallization with an acid. The invention also relates to N-methylformamide-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine and to its use to obtain racemic sertraline.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: July 17, 2001
    Assignee: Catalys
    Inventor: Patrick Bigot
  • Patent number: 6262295
    Abstract: A process for the preparation of a racemic or optically active compound of the formula where the group R1 is an unsubstituted or a halogen substituted C1-4-alkyl, a C1-4-alkoxy, an aryl, an arylalkyl, an aryloxy, or arylalkylloxy.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: July 17, 2001
    Assignee: Lonza A.G.
    Inventors: Christine Bernegger, Eva Maria Urban, Olwen Mary Birch, Kurt Burgdorf, Frank Brux, Kay-Sara Etter, Pierre Bossard, Walter Brieden, Laurent Duc, John Gordon, Colm O'Murchu, Yves Guggisberg
  • Patent number: 6252112
    Abstract: A novel process for the preparation of (1S, 4R)- or (1R, 4S)-4-(2-amino-6-chloro-9H-purin-9-yl)-2 -cyclopentene-1-methanol of the formula is described.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: June 26, 2001
    Assignee: Lonza A.G.,
    Inventors: Christine Bernegger, Eva Maria Urban, Olwen Mary Birch, Kurt Burgdorf, Frank Brux, Kay-Sara Etter, Pierre Bossard, Walter Brieden, Laurent Duc, John Gordon, Colm O'Murchu, Yves Guggisberg
  • Patent number: 6235925
    Abstract: Using the process according to the invention, it is possible to provide, with few reaction steps, a novel route to &agr;-substituted ring systems which optionally have further substituents.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: May 22, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Christoph Gürtler, Manfred Jautelat, Helmut Greiving, Herbert Hugl
  • Patent number: 6137007
    Abstract: A novel process for the preparation of (1S,4R)- or (1R,4S)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol of the formulae ##STR1## is described. This entails in the first stage (.+-.)-2-azabicyclo[2.2.1]hept-5-en-3-one of the formula ##STR2## being acylated to give a (.+-.)-2-azabicyclo[2.2.1]hept-5-en-3-one derivative of the general formula ##STR3## in which R.sup.1 denotes C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy, aryl or aryloxy, the latter being reduced in the second stage to give a cyclopentene derivative of the general formula ##STR4## in which R.sup.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: October 24, 2000
    Assignee: Lonza AG
    Inventors: Christine Bernegger, Eva Maria Urban, Olwen Mary Birch, Knut Burgdorf, Frank Brux, Kay-Sara Etter, Pierre Bossard, Walter Brieden, Laurent Duc, John Gordon, Colm O'Murchu, Yves Guggisberg
  • Patent number: 5998653
    Abstract: Compounds of the formula ##STR1## are useful as intermediates to new herbicidal 4-benzoylisoxazoles.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: December 7, 1999
    Assignee: Rhone Poulenc Agriculture Limited
    Inventors: Angela Jacqueline Bailey, Michael Gingell, David William Hawkins
  • Patent number: 5939554
    Abstract: A method for preparing a diarylalanine compound is provided. The method includes reacting a diarylaminopropanediol with a reducing agent to form a diarylaminopropanol compound and/or contacting a serine ester derivative with an aryl metal reagent to form diarylaminopropanediol. A diarylmethyloxazolidinone compound is also provided.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: August 17, 1999
    Assignee: NDSU Research Foundation
    Inventors: Mukund P. Sibi, Prasad K. Despande, Anthony J. LaLoggia
  • Patent number: 5900507
    Abstract: The present invention relates to a process for the preparation of 1-amino-1-methyl-3(4)-aminomethyl cyclohexane (AMCA) bya) catalytically hydrogenating 1-formamido-1-methyl-3(4)-cyano cyclohexane (FMC) in a first reaction stage to form 1-formamido-1-methyl-3(4)-aminomethyl cyclohexane (FMA), 1-amino-1-methyl-3(4)-formamidomethyl cyclohexane (AMF), 1-formamido-1-methyl-3(4)-formamidomethyl cyclohexane (FMF) and/or AMCA, andb) reacting FMA, AMF and/or FMF in a second reaction stage with an alkaline compound to from AMCA and a formic acid derivative, andc) separating the reaction mixture obtained in step b) into components by fractional distillation and/or by crystallization and filtration.The present invention is also relates to carrying the hydrogenation reaction of step a) in the presence of a formulating agent to form 1-formamido-1-methyl-3(4)-formamidomethyl cyclohexane (FMF).
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: May 4, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Konrad Fischer, Oswald Wilmes, Dieter Arlt, Carl Casser, Peter Maas, Pierre Woestenborghs, Theo Van Der Knaap, Raf Reintjens
  • Patent number: 5856575
    Abstract: This invention provides a process for the manufacture of N-acetyl amino phenol, which process comprises reacting an appropriate phenol and an amide in the presence of a heteropoly acid or its alkali metal salt catalyst.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: January 5, 1999
    Assignee: Council of Scientific Industrial Research
    Inventors: Sarada Gopinathan, Changaramponnath Gopinathan, Joseph Kuruvilla, Sanjeevani Amrit Pardhy, Paul Ratnasamy
  • Patent number: 5852194
    Abstract: The present invention relates to new N-substituted cis-N-propenyl-acetamides of the general formula (I) ##STR1## in which R.sup.1 represents in each case optionally substituted alkyl, -C(alkyl).sub.2 -alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl or hetarylalkyl;a process for their preparation, and their use for the preparation of 2-chloro-5-methyl-pyridine.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: December 22, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventor: Reinhard Lantzsch
  • Patent number: 5753652
    Abstract: The invention relates to compounds of formula ##STR1## and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: May 19, 1998
    Assignee: Novartis Corporation
    Inventors: Alexander Fassler, Guido Bold, Marc Lang, Shripad Bhagwat, Peter Schneider
  • Patent number: 5753709
    Abstract: Certain N-acyl 2-aryl cyclopropylmethylamine derivatives are useful as melatonergic agents.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: May 19, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel J. Keavy, Michael F. Parker, Ronald J. Mattson, Graham Johnson